keyword
https://read.qxmd.com/read/37584847/non-cgrp-antagonist-non-triptan-options-for-migraine-disease-treatment-clinical-considerations
#21
REVIEW
Ellen E Ingram, Brooke E Bocklud, Sarah C Corley, Mallory A Granier, Elisa E Neuchat, Shahab Ahmadzadeh, Sahar Shekoohi, Alan D Kaye
PURPOSE OF REVIEW: Although the association between CGRP and migraine disease is well-known and studied, therapies can target other pathways to minimize migraine symptoms. It is important to understand the role of these medications as options for migraine treatment and the varied mechanisms by which symptoms can be addressed. In the present investigation, the role of non-CGRP antagonist/non-triptan options for migraine disease therapy is reviewed, including NSAIDs, ß-blockers, calcium channel blockers, antidepressants, and antiepileptics...
August 16, 2023: Current Pain and Headache Reports
https://read.qxmd.com/read/37582724/trajectory-of-blood-pressure-after-initiating-anti-calcitonin-gene-related-peptide-treatment-of-migraine-a-target-trial-emulation-from-the-veterans-health-administration
#22
JOURNAL ARTICLE
Kaicheng Wang, Brenda T Fenton, Vinh X Dao, Alexander B Guirguis, Sarah E Anthony, Melissa Skanderson, Jason J Sico
BACKGROUND: Calcitonin gene-related peptide (CGRP) is involved in migraine pathophysiology and blood pressure regulation. Although clinical trials have established the cardio-cerebrovascular safety profile of anti-CGRP treatment, limited high-quality real-world evidence exists on its long-term effects on blood pressure (BP). To address this gap, we examined the safety of anti-CGRP treatment on BP in patients with migraine headache in the Veterans Health Administration (VHA). METHODS: We emulated a target trial of patients who initiated anti-CGRP treatment or topiramate for migraine prevention between May 17th, 2018 and February 28th, 2023...
August 15, 2023: Journal of Headache and Pain
https://read.qxmd.com/read/37575009/antiseizure-medications-as-migraine-preventatives-a-call-for-action-for-a-teratogenic-and-neurodevelopmental-risk-removal
#23
JOURNAL ARTICLE
William Wells-Gatnik, Paolo Martelletti
INTRODUCTION: A recent study has demonstrated an increased risk of neurodevelopmental disorders, including autism spectrum disorder, in individuals exposed to either valproate or topiramate monotherapy. Regulatory bodies have initiated a review to reassess the safety of topiramate exposure during pregnancy. These novel findings raise concerns regarding the recommendation of antiseizure medications in women of childbearing potential. This manuscript highlights current research defining concerns specific to the use of valproate and topiramate in women of childbearing potential...
August 14, 2023: Expert Opinion on Drug Safety
https://read.qxmd.com/read/37489383/management-of-migraine-associated-vestibulocochlear-disorders
#24
REVIEW
Kayla K Umemoto, Karen Tawk, Najva Mazhari, Mehdi Abouzari, Hamid R Djalilian
Migraine is a chronic neurological disorder that frequently coexists with different vestibular and cochlear symptoms (sudden hearing loss, tinnitus, otalgia, aural fullness, hyperacusis, dizziness, imbalance, and vertigo) and disorders (recurrent benign positional vertigo, persistent postural perceptual dizziness, mal de debarquement, and Menière's disease). Despite evidence of an epidemiological association and similar pathophysiology between migraine and these vestibulocochlear disorders, patients suffering from migraine-related symptoms are usually underdiagnosed and undertreated...
July 19, 2023: Audiology Research
https://read.qxmd.com/read/37466369/an-isotope-dilution-liquid-chromatography-tandem-mass-spectrometry-id-lc-ms-ms-based-candidate-reference-measurement-procedure-for-the-quantification-of-topiramate-in-human-serum-and-plasma
#25
JOURNAL ARTICLE
Linda Salzmann, Tino Spescha, Neeraj Singh, Anja Kobel, Vanessa Fischer, Tobias Schierscher, Friederike Bauland, Andrea Geistanger, Lorenz Risch, Christian Geletneky, Christoph Seger, Judith Taibon
OBJECTIVES: Topiramate is an antiepileptic drug (AED) used for the monotherapy or adjunctive treatment of epilepsy and for the prophylaxis of migraine. It has several pharmacodynamic properties that contribute to both its clinically useful properties and observed adverse effects. Accurate measurement of its concentration is therefore essential for dose adjustment/optimisation of AED therapy. Our aim was to develop and validate a novel reference measurement procedure (RMP) for the quantification of topiramate in human serum and plasma...
July 19, 2023: Clinical Chemistry and Laboratory Medicine: CCLM
https://read.qxmd.com/read/37441061/refractory-jeavons-syndrome-from-birth-symptomatic-to-plcb1-mutation
#26
REVIEW
Alexandria L Spurgeon, Shannon F Keaveney, Yu-Tze Ng
Jeavons syndrome is a common, often misdiagnosed or overlooked epileptic syndrome presenting with a triad of eyelid myoclonia with or without absence seizures, eye closure-induced EEG paroxysms, and photosensitivity. We present a seven-year-old female who presented with eyelid myoclonia evident since birth with absence seizures and migraines with associated photosensitivity. An EEG with photic stimulation confirmed the diagnosis of Jeavons syndrome. Genetic testing showed a heterozygous mutation in the PLCB1 gene which has been linked to early onset epilepsies and encephalopathic epilepsies...
2023: Child Neurology Open
https://read.qxmd.com/read/37378252/topiramate-induced-coma-in-a-39-year-old-female-patient-burst-suppression-on-eeg
#27
Abdullah M Hakoun
Reported cases of topiramate ingestion resulting in coma and generalized convulsive status epilepticus are very rare. Such a phenomenon of a relatively safe antiepileptic drug (AED) causing serious neurological compromise should be carefully reviewed. A 39-year-old female with a history of uncontrolled epilepsy, migraine headaches, hypothyroidism, obsessive-convulsive disorder, and depression presented with generalized tonic-clonic seizures that progressed to status epilepticus and coma thereafter. She was intubated due to a depressed level of consciousness and transferred afterward to our hospital...
May 2023: Curēus
https://read.qxmd.com/read/37368102/narrative-review-of-topiramate-clinical-uses-and-pharmacological-considerations
#28
REVIEW
Nathan Z Pearl, Caroline P Babin, Nicole T Catalano, James C Blake, Shahab Ahmadzadeh, Sahar Shekoohi, Alan D Kaye
Due to the diverse mechanisms of action of antiseizure drugs, there has been a rise in prescriptions of these drugs for non-epileptic pathologies. One drug that is now being used for a variety of conditions is topiramate. This is a narrative review that used PubMed, Google Scholar, MEDLINE, and ScienceDirect to review literature on the clinical and pharmacologic properties of topiramate. Topiramate is a commonly prescribed second-generation antiseizure drug. The drug works through multiple pathways to prevent seizures...
September 2023: Advances in Therapy
https://read.qxmd.com/read/37283266/prescribing-trends-of%C3%A2-antiseizure-drugs-in%C3%A2-women-veterans-with-epilepsy
#29
JOURNAL ARTICLE
Maria Raquel Lopez, Anne C VanCott, Megan E Amuan, Samin Panahi, Amy Henion, Mary Jo Pugh
OBJECTIVE: Antiseizure medications (ASMs) are frequently used for other indications, such as migraine, pain syndromes, and psychiatric disorders. Possible teratogenic effects are therefore of wide concern and the risks imposed by the medications must be weighed against the risk with the disorder treated. It is our objective to update family practitioners on the implications of starting ASM for women with epilepsy during childbearing age. We hypothesized that clinicians would prescribe ASM based on avoiding teratogenesis and treating associated comorbidities simultaneously...
June 6, 2023: Military Medicine
https://read.qxmd.com/read/37266989/comparison-table-some-drugs-for-migraine-prevention-in-adults
#30
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
June 12, 2023: Medical Letter on Drugs and Therapeutics
https://read.qxmd.com/read/37235366/safety-of-onabotulinumtoxin-a-in-chronic-migraine-a-systematic-review-and-meta-analysis-of-randomized-clinical-trials
#31
REVIEW
Maria Tiziana Corasaniti, Giacinto Bagetta, Pierluigi Nicotera, Assunta Tarsitano, Paolo Tonin, Giorgio Sandrini, Gary W Lawrence, Damiana Scuteri
Some 14% of global prevalence, based on high-income country populations, suffers from migraine. Chronic migraine is very disabling, being characterized by at least 15 headache days per month of which at least 8 days present the features of migraine. Onabotulinumtoxin A, targeting the machinery for exocytosis of neurotransmitters and neuropeptides, has been approved for use in chronic migraine since 2010. This systematic review and meta-analysis appraises the safety of onabotulinumtoxin A treatment for chronic migraine and the occurrence of treatment-related adverse events (TRAEs) in randomized, clinical studies in comparison with placebo or other comparators and preventative treatments according to the most updated Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 2020 recommendations...
May 12, 2023: Toxins
https://read.qxmd.com/read/37212943/a-retrospective-real-life-multicenter-study-on-concurrent-oral-preventive-treatments-in-patients-with-chronic-migraine-treated-with-onabotulinumtoxina
#32
JOURNAL ARTICLE
Lucas Hendrik Overeem, Raffaele Ornello, Maria Magdalena Pocora, Uwe Reuter, Simona Sacco, Cristina Tassorelli, Aud Nome Dueland, Bianca Raffaelli, Daniele Martinelli
BACKGROUND AND OBJECTIVE: OnabotulinumtoxinA (BoNTA) is a relatively safe and effective treatment for chronic migraine. The local mode of action of BoNTA favors the combination of oral treatments with systemic action. However, little is known about the possible interactions with other preventive treatments. The objective of the study was to describe the use of oral preventive treatments in patients with chronic migraine treated with BoNTA in routine clinical care and discuss the tolerability and efficacy according to the presence or absence of concomitant oral treatments...
May 22, 2023: CNS Drugs
https://read.qxmd.com/read/37210713/pharmacokinetics-and-safety-of-coadministered-atogepant-and-topiramate-in-healthy-participants-a-phase-1-open-label-drug-drug-interaction-study
#33
JOURNAL ARTICLE
Ramesh Boinpally, Danielle McGeeney, Lisa Borbridge, Joel Trugman
Atogepant, an oral calcitonin gene-related peptide receptor antagonist, and topiramate, a commonly used oral antiepileptic, are approved as preventive migraine treatments. Given the distinct mechanisms of action of these treatments, it is possible that they may be coprescribed for migraine. This open-label, single-center, 2-cohort, phase 1 trial evaluated the potential pharmacokinetic (PK) 2-way drug-drug interactions (DDIs), safety, and tolerability of atogepant and topiramate in healthy adults. Participants received atogepant 60 mg once daily and topiramate 100 mg twice daily...
May 21, 2023: Clinical Pharmacology in Drug Development
https://read.qxmd.com/read/37208596/the-comparative-effectiveness-of-migraine-preventive-drugs-a-systematic-review-and-network-meta-analysis
#34
JOURNAL ARTICLE
Christian Lampl, Antoinette MaassenVanDenBrink, Christina I Deligianni, Raquel Gil-Gouveia, Tanvir Jassal, Margarita Sanchez-Del-Rio, Uwe Reuter, Derya Uluduz, Jan Versijpt, Dena Zeraatkar, Simona Sacco
OBJECTIVE: While there are several trials that support the efficacy of various drugs for migraine prophylaxis against placebo, there is limited evidence addressing the comparative safety and efficacy of these drugs. We conducted a systematic review and network meta-analysis to facilitate comparison between drugs for migraine prophylaxis. METHODS: We searched MEDLINE, EMBASE, CENTRAL, and clinicaltrials.gov from inception to August 13, 2022, for randomized trials of pharmacological treatments for migraine prophylaxis in adults...
May 19, 2023: Journal of Headache and Pain
https://read.qxmd.com/read/37125397/high-dose-vitamin-d-3-supplementation-in-relapsing-remitting-multiple-sclerosis-a-randomised-clinical-trial
#35
JOURNAL ARTICLE
Sandra D Cassard, Kathryn C Fitzgerald, Peiqing Qian, Susan A Emrich, Christina J Azevedo, Andrew D Goodman, Elizabeth A Sugar, Daniel Pelletier, Emmanuelle Waubant, Ellen M Mowry
BACKGROUND: Vitamin D insufficiency is associated with risk of multiple sclerosis (MS) relapse; whether supplementation influences prognosis is unknown. The Vitamin D to Ameliorate MS (VIDAMS) trial aimed to determine if high dose (5000 International Units (IU)/day) versus low dose (600 IU/day) vitamin D3, added to daily glatiramer acetate (GA), reduced the risk of clinical relapse in people with established relapsing remitting MS (RRMS) over 96 weeks. METHODS: VIDAMS is a randomised, phase 3, double-blind, multi-centre, controlled trial conducted at sixteen neurology clinics in the United States...
May 2023: EClinicalMedicine
https://read.qxmd.com/read/36923740/outcome-of-topiramate-in-migraine-prophylaxis
#36
JOURNAL ARTICLE
Etedal Ahmed A Ibrahim, Wadia Abdalla Balla Elhardallo, Khabab Abbasher Hussien Mohamed Ahmed, Mohammed E Abdalla Omer, Mohammed Mahmmoud Fadelallah Eljack
UNLABELLED: Topiramate is an antiepileptic medication originally and one of the first-line drugs for migraine prophylaxis. Herein, we aimed to assess the outcome of topiramate in migraine prophylaxis by evaluating the reduction in frequency and/or severity of attacks and addressing the most common adverse effects associated with it. METHODS: A descriptive, prospective hospital-based study was conducted at Ibrahim Malik Hospital, National Center of Neurological Disease and Sciences from October 2018 to May 2019...
March 2023: Annals of Medicine and Surgery
https://read.qxmd.com/read/36856015/randomized-controlled-studies-evaluating-topiramate-botulinum-toxin-type-a-and-mabs-targeting-cgrp-in-patients-with-chronic-migraine-and-medication-overuse-headache-a-systematic-review-and-meta-analysis
#37
REVIEW
Samita Giri, Erling Tronvik, Mattias Linde, Sindre Andre Pedersen, Knut Hagen
BACKGROUND: This systematic review focuses on chronic migraine patients with medication overuse headache using, respectively, topiramate, botulinum toxin type A, and human monoclonal antibodies targeting calcitonin gene-related peptide or its receptor. METHODS: A systematic search was conducted in the databases CENTRAL, MEDLINE, Embase and Web of Science until May 2022. We included randomized controlled trials reporting the outcomes of change in monthly headache/migraine days, ≥50% response rates and change in medication overuse status...
April 2023: Cephalalgia: An International Journal of Headache
https://read.qxmd.com/read/36791365/diagnosis-and-management-of-cyclic-vomiting-syndrome-a-critical-review
#38
REVIEW
Rosita Frazier, B U K Li, Thangam Venkatesan
Cyclic vomiting syndrome (CVS) is a chronic disorder of gut-brain interaction characterized by recurrent disabling episodes of nausea, vomiting, and abdominal pain. CVS affects both children and adults with a prevalence of approximately 2% in the United States. CVS is more common in female individuals and affects all races. The pathophysiology of CVS is unknown and a combination of genetic, environmental, autonomic, and neurohormonal factors is believed to play a role. CVS is also closely associated with migraine headaches and likely have a shared pathophysiology...
July 1, 2023: American Journal of Gastroenterology
https://read.qxmd.com/read/36759321/genome-wide-dna-methylation-analysis-in-an-antimigraine-treated-preclinical-model-of-cortical-spreading-depolarization
#39
JOURNAL ARTICLE
Marta Vila-Pueyo, Ester Cuenca-León, Ana C Queirós, Marta Kulis, Cèlia Sintas, Bru Cormand, José Ignacio Martín-Subero, Patricia Pozo-Rosich, Noèlia Fernàndez-Castillo, Alfons Macaya
BACKGROUND: Cortical spreading depolarization, the cause of migraine aura, is a short-lasting depolarization wave that moves across the brain cortex, transiently suppressing neuronal activity. Prophylactic treatments for migraine, such as topiramate or valproate, reduce the number of cortical spreading depression events in rodents. OBJECTIVE: To investigate whether cortical spreading depolarization with and without chronic treatment with topiramate or valproate affect the DNA methylation of the cortex...
February 2023: Cephalalgia: An International Journal of Headache
https://read.qxmd.com/read/36757131/impact-of-preventive-pill-based-treatment-on-migraine-days-a-secondary-outcome-study-of-the-childhood-and-adolescent-migraine-prevention-champ-trial-and-a-comparison-of-self-report-to-nosology-derived-assessments
#40
JOURNAL ARTICLE
Robert C Gibler, James L Peugh, Christopher S Coffey, Leigh Ann Chamberlin, Dixie Ecklund, Elizabeth Klingner, Jon Yankey, Leslie L Korbee, Marielle Kabbouche, Joanne Kacperski, Linda L Porter, Brooke L Reidy, Andrew D Hershey, Scott W Powers
OBJECTIVE: To examine group differences in self-reported migraine days among youth who completed the Childhood and Adolescent Migraine Prevention (CHAMP) trial prior to its closure and explore the relationship between self-reported and "nosology-derived" (i.e., International Classification of Headache Disorders, 3rd edition [ICHD-3]) migraine days. BACKGROUND: The CHAMP trial compared amitriptyline and topiramate to placebo for migraine prevention in youth and proposed to analyze change in migraine days as a secondary outcome...
February 9, 2023: Headache
keyword
keyword
165817
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.